Journal
CANCER CELL
Volume 35, Issue 4, Pages 545-557Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2019.01.019
Keywords
-
Categories
Funding
- Swiss National Science Foundation through the National Center of Competence in Research (NCCR) RNA Disease''
- University Hospital of Bern
- Helmut Horten Stiftung
- Swiss Cancer League
- Medical Faculty of the University
Ask authors/readers for more resources
Long non-coding RNAs (lncRNAs) represent a huge reservoir of potential cancer targets. Such onco-lncRNAs have resisted traditanal RNAi methods, but CRIrPR-Cas9 genome editing now promises functional screens at high throughput and low cost. The unique biology of lncRNAs demands screening strategies distinct from protein-coding genes. The first such screens have identified hundreds of onco-lncRNAs promoting cell proliferation and drug resistance. Ongoing developments will further improve screen performance and translational relevance. This Review aims to highlight the potential of CRISPR screening technology for discovering new onco-lncRNAs, and to guide molecular oncologists wishing to apply it to their cancer of interest.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available